Healthspan is becoming a more useful way to assess the ageing opportunity than lifespan alone. Lifespan is the number of years a person lives. Healthspan is the number of those years spent in good health, with the ability to remain active and independent.
Longer lives can increase demand for healthcare, care services and chronic disease management. Longer, healthier lives can shift demand towards prevention, early intervention, mobility, nutrition and tools that help people maintain function.
Ageing is linked to a higher risk of conditions such as heart disease, cancer, dementia, diabetes and frailty. Research into healthspan looks at the underlying processes that may contribute to several of these conditions. One area of focus is cellular senescence, where damaged cells stop dividing but remain in the body. These cells can have useful effects in some circumstances, including helping to prevent cancer. However, when they build up over time, they may contribute to inflammation and tissue decline.
Companies that can target the biology of ageing may have the potential to influence more than one age-related condition. At the same time, the field remains scientifically complex.
Healthspan is also linked to behaviour and daily health management. Exercise, nutrition, sleep and social connection all play a role in supporting healthier ageing. This creates opportunities across healthcare services, diagnostics, digital health, wellness, mobility and care delivery.
Ageing populations will continue to create demand, but the most attractive opportunities may come from companies focused on keeping people healthier for longer, not only treating disease once it appears.
Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives
